An observational study in Stroke, sponsored by University of Melbourne. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by University of Melbourne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.
Among the 122 studies in Stroke with a site in Australia, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2024, is one of 13 observational ones, reaches primary completion later than 9 of the 28 other live ones, and was the 113th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:
University of Calgary · Sites in Australia, Canada
Ages 18+
Eli Lilly and Company · Sites in Australia, Argentina, Austria and 35 more countries
Ages 50+
Pharmazz, Inc. · Sites in Australia, United States, Germany and 2 more countries
Ages 18–80
The Florey Institute of Neuroscience and Mental Health · Sites in Australia
Ages 18–55
Transverse Medical, Inc. · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 51 · Phase 4 10
First in 1996; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 146 is close to the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 569 across the 108 interventional studies, 626 across the 13 observational. Of the 87 that completed or were terminated, 34 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 122 have an industry lead sponsor. The 10 most frequent:
University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.
University of Melbourne has 5 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Stroke with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT06527261University of MelbourneElectronic Capturing of Activities During REhabilitation for Upper Limb After Stroke | 2026-12 |
| NCT06495671University of MelbourneAustralasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke | 2026-12-31 |
| NCT07019493The Florey Institute of Neuroscience and Mental HealthYoung Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke | 2026-12-31 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 122 studies in Stroke with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective cohort study to determine the feasibility of accurate, complete, and timely real-time electronic capturing of upper limb motor intervention sessions during usual care. In clinical trials accurate reporting of usual care for people with stroke is scarce, thus understanding the control group compared to the experimental group is poor. The unit of measure in this study is therapy sessions, where a clinician is providing usual care to a patient.
The observed sessions will occur in two Austin Health settings: Acute at Austin Hospital; subacute, across Royal Talbot Rehabilitation Centre or the Heidelberg Repatriation Hospital. For each session, patient characteristics, dose and content of upper limb interventions will be electronically captured in REDCap. Additionally, the sessions will be video recorded to allow a second rater to assess feasibility. The secondary aim is to determine if there is an association between the dose and content of upper limb intervention sessions and the contextual factors of stroke patients. Two participant groups will be recruited: Stroke patients and Clinicians (Occupational Therapists and Allied Health Assistants).
This is a prospective observational cohort study to determine the feasibility of accurate, complete, and timely real-time electronic capturing of upper limb motor intervention sessions during usual care.
In clinical trials accurate reporting of usual care for people with stroke is scarce, thus understanding the control group compared to the experimental group is poor.
The unit of measure is the therapy sessions, where a clinician is providing usual care to a patient. The observed sessions will occur across two Austin Health settings. Setting A: Acute at Austin Hospital, and Setting B: Subacute at Royal Talbot Rehabilitation Centre or the Heidelberg Repatriation Hospital.
For each session, patient characteristics, the multiple dimensions of dose, and the content of usual care motor upper limb interventions will be electronically captured in REDCap. The observed sessions will be video recorded and a second rater will review the session for dose data accuracy. Secondary to determining feasibility, the dose and content data from observed sessions will be analysed to investigate the association of context factors such as setting and upper limb impairment severity.
As such, this study aims to answer the following research questions:
Group 1: Stroke patients These participants will be selected from inpatients within the tertiary health service of Austin Health in Melbourne, Victoria, Australia. They may be located at the acute setting: Austin hospital, Or subacute setting: Heidelberg repatriation hospital or Royal Talbot rehabilitation Centre.
Group 2: Clinicians Clinicians will be invited to participate if they are an Occupational Therapist or allied health assistant working at Austin health with the stroke patient population.
Group 1: Stroke patients
Inclusion Criteria:
Exclusion Criteria:
Group 2: Clinicians
Inclusion criteria
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observed sessions for patients who are in the acute inpatient setting. Each session will include a patient and a clinician
Other: Real-time electronic data input into REDCap
Observed sessions for patients who are in the subacute inpatient setting. Each session will include a patient and a clinician
Other: Real-time electronic data input into REDCap
During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions. The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation.
Feasibility of real-time electronic data input of usual care session dose
A single binary composite primary outcome, where feasibility is defined by 90% of sessions achieving ALL of: 1. Binary outcome of Accuracy: ≤10% difference in dose between electronic data and second-rater data from a video recording of the session as defined by the decision algorithm. 2. Binary outcome of Completeness: ≥90% of the electronic data completed by clinicians as defined by the decision algorithm. 3. Binary outcome of Timeliness: ≤10% of session time is spent completing the electronic record or rated non-burdensome by the clinician as defined by the decision algorithm.
Time frame: Each feasibility session will take up to one hour.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2024; primary completion for Dec 2026, 29 months later.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 29 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Melbourne